Related Experiment Videos
Effect of loperamide on stool output and duration of acute infectious diarrhea in infants
1Department of Paediatrics and Child Health, University of Cape Town, South Africa.
Insights
Loperamide effectively reduced diarrhea duration and stool output in infants. However, higher doses raised safety concerns, including ileus and vomiting, warranting caution in pediatric acute diarrhea treatment.
Area of Science:
- Pediatric Gastroenterology
- Clinical Pharmacology
Background:
- Acute diarrhea is a common pediatric illness.
- Loperamide is an antimotility agent used for diarrhea.
Purpose of the Study:
- To evaluate the efficacy and safety of higher-than-recommended loperamide doses in infants with acute diarrhea.
Main Methods:
- A randomized controlled trial comparing loperamide (0.8 mg/kg/day) plus fluid therapy with fluid therapy alone in 60 infants.
- Stool output and diarrhea duration were primary outcome measures.
Main Results:
- Infants receiving loperamide showed significantly shorter diarrhea duration (median 2.5 vs 6.0 days) and lower stool output.
- Adverse events included ileus in one infant and severe vomiting in another; drowsiness occurred in four infants.
Conclusions:
- Loperamide demonstrated efficacy in reducing pediatric acute diarrhea severity and duration.
- Concerns regarding loperamide safety in young infants necessitate careful consideration of dosage and monitoring.
Abstract:
This study was designed to assess the effect of loperamide, given to infants in higher than recommended doses, on the severity and duration of acute diarrhea. Thirty infants with acute diarrhea and dehydration were given loperamide (0.8 mg/kg/day), in addition to standard fluid therapy, for 48 hours after admission to the hospital. The stool output in grams per kilograms of body weight per day and the duration of diarrhea in these infants were compared with those in 30 matched control infants receiving only standard fluid therapy. Two infants given loperamide had to be withdrawn from the trial because ileus developed in one and the other had persistent severe vomiting. In four other infants receiving loperamide, drowsiness developed but resolved rapidly on discontinuation of the drug. Infants receiving loperamide had a shorter duration of diarrhea (median 2.5 vs 6.0 days) and lower daily stool output than the control subjects had. The study confirmed the efficacy of loperamide in reducing the duration and severity of diarrhea but raised doubts regarding its safety in the treatment of young infants.